艾伯维2025年第一季度财务业绩报告显示,公司全球净收入达133.43亿美元,同比增长8.4%。调整后稀释每股收益为2.46美元,同比增长6.5%。免疫学产品组合表现强劲,全球净收入62.64亿美元,同比增长16.6%,其中Skyrizi和Rinvoq分别增长70.5%和57.2%,但Humira收入下滑50.6%,连续三个季度低于销售预期。神经科学产品组合全球净收入22.82亿美元,同比增长...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.